Lifecare Q2 2024 - High activity – initial positive signs from longevity trials
2024-08-28 11:21:00
Redeye updates its view on Lifecare following the Q2 report and recent company developments, including confirmed sensor longevity of nine weeks in dogs, a strategic cooperation, and a new patent filing, among other things.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/